As shown in Figure 4G that patients with JIA had a decreased plasma concentration of cf-DNA after six months of treatment with TNF-α inhibitors (adalimumab or etanercept), along with significantly improving disease activity (reduced JADAS27) (n = 23, p < 0.0001), indicating that TNF-α inhibitors can effectively inhibit NET formation in vivo. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.